These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 15908973

  • 1. Rituximab mediates in vitro antileukemic activity in pediatric patients after allogeneic transplantation.
    Pfeiffer M, Stanojevic S, Feuchtinger T, Greil J, Handgretinger R, Barbin K, Jung G, Martin D, Niethammer D, Lang P.
    Bone Marrow Transplant; 2005 Jul; 36(2):91-7. PubMed ID: 15908973
    [Abstract] [Full Text] [Related]

  • 2. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2.
    Golay J, Manganini M, Facchinetti V, Gramigna R, Broady R, Borleri G, Rambaldi A, Introna M.
    Haematologica; 2003 Sep; 88(9):1002-12. PubMed ID: 12969808
    [Abstract] [Full Text] [Related]

  • 3. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
    Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E, Czuczman MS.
    Clin Cancer Res; 2003 Dec 01; 9(16 Pt 1):5866-73. PubMed ID: 14676108
    [Abstract] [Full Text] [Related]

  • 4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May 01; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 5. Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity.
    Lv M, Lin Z, Qiao C, Gen S, Lang X, Li Y, Feng J, Shen B.
    Cancer Lett; 2010 Aug 01; 294(1):66-73. PubMed ID: 20202740
    [Abstract] [Full Text] [Related]

  • 6. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
    Treon SP, Mitsiades C, Mitsiades N, Young G, Doss D, Schlossman R, Anderson KC.
    J Immunother; 2001 Aug 01; 24(3):263-71. PubMed ID: 11394505
    [Abstract] [Full Text] [Related]

  • 7. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
    Lopes de Menezes DE, Denis-Mize K, Tang Y, Ye H, Kunich JC, Garrett EN, Peng J, Cousens LS, Gelb AB, Heise C, Wilson SE, Jallal B, Aukerman SL.
    J Immunother; 2007 Jan 01; 30(1):64-74. PubMed ID: 17198084
    [Abstract] [Full Text] [Related]

  • 8. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity.
    Li B, Shi S, Qian W, Zhao L, Zhang D, Hou S, Zheng L, Dai J, Zhao J, Wang H, Guo Y.
    Cancer Res; 2008 Apr 01; 68(7):2400-8. PubMed ID: 18381448
    [Abstract] [Full Text] [Related]

  • 9. Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects.
    Ratanatharathorn V, Pavletic S, Uberti JP.
    Cancer Treat Rev; 2009 Dec 01; 35(8):653-61. PubMed ID: 19682801
    [Abstract] [Full Text] [Related]

  • 10. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
    Moga E, Alvarez E, Cantó E, Vidal S, Rodríguez-Sánchez JL, Sierra J, Briones J.
    Exp Hematol; 2008 Jan 01; 36(1):69-77. PubMed ID: 17959301
    [Abstract] [Full Text] [Related]

  • 11. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity.
    van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB.
    Clin Cancer Res; 2006 Jul 01; 12(13):4027-35. PubMed ID: 16818702
    [Abstract] [Full Text] [Related]

  • 12. The impact of acute and chronic graft-versus-host disease on normal and malignant B-lymphoid precursors after allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia.
    Sánchez-García J, Serrano J, Gómez P, Martínez F, Martín C, Román-Gómez J, Rodríguez A, Herrera C, García JM, Alvarez MA, Torres A.
    Haematologica; 2006 Mar 01; 91(3):340-7. PubMed ID: 16531257
    [Abstract] [Full Text] [Related]

  • 13. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab.
    Carnahan J, Stein R, Qu Z, Hess K, Cesano A, Hansen HJ, Goldenberg DM.
    Mol Immunol; 2007 Feb 01; 44(6):1331-41. PubMed ID: 16814387
    [Abstract] [Full Text] [Related]

  • 14. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
    Shi YX, Zhang XS, Xia JC, Li YQ, Xu RH, Han WJ, Zhang JH, Guan ZZ, Jiang WQ.
    Ai Zheng; 2007 Aug 01; 26(8):837-42. PubMed ID: 17697543
    [Abstract] [Full Text] [Related]

  • 15. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
    Maddipatla S, Hernandez-Ilizaliturri FJ, Knight J, Czuczman MS.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4556-64. PubMed ID: 17671142
    [Abstract] [Full Text] [Related]

  • 16. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R, Hagenbeek A.
    Eur J Haematol Suppl; 2007 Jan 01; (67):5-14. PubMed ID: 17206982
    [Abstract] [Full Text] [Related]

  • 17. [Interleukin-2 improves the antitumor activity of Rituximab in patients with B-cell lymphoma in vitro].
    Zhang WX, Guo J, Lin BH, Meng SN, Wang XP, Xie Y, Zheng W, Zhang YT, Zhu J.
    Zhonghua Xue Ye Xue Za Zhi; 2007 Jan 01; 28(1):41-4. PubMed ID: 17649726
    [Abstract] [Full Text] [Related]

  • 18. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
    Flavell DJ, Warnes SL, Bryson CJ, Field SA, Noss AL, Packham G, Flavell SU.
    Br J Haematol; 2006 Jul 01; 134(2):157-70. PubMed ID: 16771848
    [Abstract] [Full Text] [Related]

  • 19. Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia.
    Kebriaei P, Saliba RM, Ma C, Ippoliti C, Couriel DR, de Lima M, Giralt S, Qazilbash MH, Gajewski JL, Ha CS, Champlin RE, Khouri IF.
    Bone Marrow Transplant; 2006 Aug 01; 38(3):203-9. PubMed ID: 16799614
    [Abstract] [Full Text] [Related]

  • 20. Antiviral activity against CMV-infected fibroblasts in pediatric patients transplanted with CD34(+)-selected allografts from alternative donors.
    Lang P, Griesinger A, Hamprecht K, Feuchtinger T, Schumm M, Neuhäuser F, Greil J, Martin D, Handgretinger R, Niethammer D.
    Hum Immunol; 2004 May 01; 65(5):423-31. PubMed ID: 15172441
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.